Cargando…
Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert
Therapeutic guidelines indicate prostacyclin as the first line of treatment in inflammation and vascular diseases. Prostacyclins prevent formation of the platelet plug involved in primary hemostasis by inhibiting platelet activation and, combined with thromboxane, are effective vasodilators in vascu...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475780/ https://www.ncbi.nlm.nih.gov/pubmed/25381994 http://dx.doi.org/10.2174/1573406410666141110153502 |
_version_ | 1782377515294130176 |
---|---|
author | Celia, Christian Locatelli, Marcello Cilurzo, Felisa Cosco, Donato Gentile, Emanuela Scalise, Daniela Carafa, Maria Ventura, Cinzia Anna Fleury, Mathias Tisserand, Christelle Barbacane, Renato C. Fresta, Massimo Marzio, Luisa Di Paolino, Donatella |
author_facet | Celia, Christian Locatelli, Marcello Cilurzo, Felisa Cosco, Donato Gentile, Emanuela Scalise, Daniela Carafa, Maria Ventura, Cinzia Anna Fleury, Mathias Tisserand, Christelle Barbacane, Renato C. Fresta, Massimo Marzio, Luisa Di Paolino, Donatella |
author_sort | Celia, Christian |
collection | PubMed |
description | Therapeutic guidelines indicate prostacyclin as the first line of treatment in inflammation and vascular diseases. Prostacyclins prevent formation of the platelet plug involved in primary hemostasis by inhibiting platelet activation and, combined with thromboxane, are effective vasodilators in vascular damage. Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II guidelines indicates prostacyclins; in particular, Iloprost, as the first therapeutic option for treating peripheral arterial disease. However, therapeutic efficacy of Iloprost has witnessed several drawbacks that have occurred in patients receiving repeated weekly administration of the drug by intravenous infusions. Adverse reactions arose under perfusion with Iloprost for 6 h and patient compliance was drastically decreased. Biomedical devices could provide a suitable alternative to overcome these drawbacks. In particular, elastomeric pumps, filled with Iloprost isotonic solution, could slowly release the drug, thus decreasing its side effects, representing a valid alternative to hospitalization of patients affected by peripheral arterial disease. However, the home therapy treatment of patients requires long-term stability of Iloprost in solution-loaded elastomeric pumps. The aim of this work was to investigate the long-term stability of Iloprost isotonic solution in biomedical devices using Turbiscan technology. Turbiscan Lab Expert (L’Union, France) predicts the long-term stability of suspensions, emulsions and colloidal formulations by measuring backscattering and transmission of particulates dispersed in solution. The formulations were evaluated by measuring the variation of physical-chemical properties of colloids and suspensions as a function of backscattering and transmission modifications. In addition, the release profile of Iloprost isotonic solution from the biomedical device was evaluated. |
format | Online Article Text |
id | pubmed-4475780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-44757802015-06-24 Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert Celia, Christian Locatelli, Marcello Cilurzo, Felisa Cosco, Donato Gentile, Emanuela Scalise, Daniela Carafa, Maria Ventura, Cinzia Anna Fleury, Mathias Tisserand, Christelle Barbacane, Renato C. Fresta, Massimo Marzio, Luisa Di Paolino, Donatella Med Chem Article Therapeutic guidelines indicate prostacyclin as the first line of treatment in inflammation and vascular diseases. Prostacyclins prevent formation of the platelet plug involved in primary hemostasis by inhibiting platelet activation and, combined with thromboxane, are effective vasodilators in vascular damage. Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II guidelines indicates prostacyclins; in particular, Iloprost, as the first therapeutic option for treating peripheral arterial disease. However, therapeutic efficacy of Iloprost has witnessed several drawbacks that have occurred in patients receiving repeated weekly administration of the drug by intravenous infusions. Adverse reactions arose under perfusion with Iloprost for 6 h and patient compliance was drastically decreased. Biomedical devices could provide a suitable alternative to overcome these drawbacks. In particular, elastomeric pumps, filled with Iloprost isotonic solution, could slowly release the drug, thus decreasing its side effects, representing a valid alternative to hospitalization of patients affected by peripheral arterial disease. However, the home therapy treatment of patients requires long-term stability of Iloprost in solution-loaded elastomeric pumps. The aim of this work was to investigate the long-term stability of Iloprost isotonic solution in biomedical devices using Turbiscan technology. Turbiscan Lab Expert (L’Union, France) predicts the long-term stability of suspensions, emulsions and colloidal formulations by measuring backscattering and transmission of particulates dispersed in solution. The formulations were evaluated by measuring the variation of physical-chemical properties of colloids and suspensions as a function of backscattering and transmission modifications. In addition, the release profile of Iloprost isotonic solution from the biomedical device was evaluated. Bentham Science Publishers 2015-06 2015-06 /pmc/articles/PMC4475780/ /pubmed/25381994 http://dx.doi.org/10.2174/1573406410666141110153502 Text en © 2015 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Celia, Christian Locatelli, Marcello Cilurzo, Felisa Cosco, Donato Gentile, Emanuela Scalise, Daniela Carafa, Maria Ventura, Cinzia Anna Fleury, Mathias Tisserand, Christelle Barbacane, Renato C. Fresta, Massimo Marzio, Luisa Di Paolino, Donatella Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title | Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title_full | Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title_fullStr | Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title_full_unstemmed | Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title_short | Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device Through Turbiscan Lab Expert |
title_sort | long term stability evaluation of prostacyclin released from biomedical device through turbiscan lab expert |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475780/ https://www.ncbi.nlm.nih.gov/pubmed/25381994 http://dx.doi.org/10.2174/1573406410666141110153502 |
work_keys_str_mv | AT celiachristian longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT locatellimarcello longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT cilurzofelisa longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT coscodonato longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT gentileemanuela longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT scalisedaniela longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT carafamaria longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT venturacinziaanna longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT fleurymathias longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT tisserandchristelle longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT barbacanerenatoc longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT frestamassimo longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT marzioluisadi longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert AT paolinodonatella longtermstabilityevaluationofprostacyclinreleasedfrombiomedicaldevicethroughturbiscanlabexpert |